Article Text

THU0169 One-third of patients with rheumatoid arthritis eligible for a first biologic are not adherent to methotrexate: results of forget, a cross-sectional survey of 244 patients
  1. C Beauvais1,
  2. V Hautin-Monteil2,
  3. M-C Ducrot3,
  4. R-M Flipo4
  1. 1Rheumatology Department, Saint Antoine Hospital, APHP, Paris
  2. 2Roche
  3. 3Agence A+A, Boulogne-Billancourt
  4. 4Rheumatology department, Roger Salengro Hospital, Lille, France


Background Adherence to Methotrexate (MTX) is not optimal in patients with rheumatoid arthritis (RA)[1]. Low adherence may lead to insufficient response and unjustified initiation of biologics.

Objectives The objectives were 1-assess the self-reported adherence rate to MTX of RA patients insufficient responders to MTX (MTX-IR) when an initiation of biologics was being considered 2- Investigate the factors of low adherence among these patients 3- collect the physicians' estimation of their patients' adherence level.

Methods Patient recruitment was done through rheumatologists: RA patients, MTX-IR, biologic-naive, eligible for a biologic according to the rheumatologist's opinion. The rheumatologist completed a questionnaire on his practice and estimation on the patient's level of adherence and provided the patient with a self-administered questionnaire on his disease and treatments, to be sent directly to the data center. The patient's questionnaire contained the CQR19 (Compliance Questionnaire for Rheumatology [2]. The purpose of assessing adherence was not specified to the patient.

Results From May to July 2016, 78 rheumatologists recruited 269 patients who referred 244 self-administered questionnaires, 214 assessed for CQR 19 score; 200 questionnaires were completed by both patients and their rheumatologist. Patients were 72% women, mean age 54 years, 58% had at least 1 comorbidity, mean DAS28 score 4.07, mean RAID score 5.7/10. The percentage of non-adherent patients was 34%: adherence rate <80% according to the CQR.

Non-adherent patients had a higher RAID score (5.7 vs 5.0; p<0.01) whereas DAS 28 was not significantly different (4.14 vs 4.04). They more often presented osteoporosis (18% vs 4%, p<0.01), reported reluctance to take treatment (40% vs 24%, p<0.01), had more negative beliefs (40% vs 24%; p<0.01), and poor support from relatives (67% vs 84%, p<0.011). Good-adherent patients were more often followed in a private practice (31% vs 10%, p<0.01) and reported more information received from their rheumatologist (94% vs 85%, p<0.05). No correlation was found between adherence and age, subcutaneous versus oral route of administration or perceived tolerance.

88% of rheumatologists reported they detect adherence at every consultation, asking direct (76%) or open (46%) questions. Adherence was underestimated by rheumatologists: a 67% concordance was found between the rheumatologist's rating and the patient's reported adherence. Non-adherent patients to MTX were more often proposed biologic treatment in combination with MTX than patients with good compliance (91% vs 68%, p<0.01).

Conclusions This survey showed for the first time that 34% of MTX-IR patients show poor adherence to MTX at the time of the initiation of a first biologic. Negative beliefs and poor support from relatives are factors of non-adherence. Studies will be needed to understand physicians' attitudes toward non-adherence and what strategy of biologics prescription they are likely to consider.


  1. DiBenedetti D Rheumatol Ther 2015.

  2. de Klerk E et al, J Rheumatol 1999.


Acknowledgements This study was funded by Chugai Pharma France.

Disclosure of Interest C. Beauvais: None declared, V. Hautin-Monteil Employee of: Roche France, M.-C. Ducrot: None declared, R.-M. Flipo: None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.